Ascletis Reports Positive Phase I Results for ASC5...
Category : Clinical Trial Update 29 September 2026Oral IL-17A Inhibitor Shows Positive Results in 28-Day Proof-of-Concept Study Ascletis Pharma Inc...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
AI in Clinical Trials Market to Reach USD 7.32 Bil...
Category : Clinical Trial Update 28 September 2026Market Expected to Grow at 15.5% CAGR From 2026 to 2034 The global AI in Clinical Trials Market i...
Kodiak Sciences to Report Phase 3 DAYBREAK Results...
Category : Clinical Trial Update 28 September 2026Topline Results Will Evaluate Treatments for Wet Age-Related Macular Degeneration Kodiak Sciences...
Gossamer Bio submits NDA to US FDA for seralutinib...
Category : Clinical Trial Update 26 September 2026Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commer...
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Stu...
Category : Clinical Trial Update 26 September 2026Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical co...
Latest Newsletter Post
-
Takeda announces positive data from..
1 October 2026
-
Vanda Reports Positive Phase III Re..
30 September 2026
-
Airway Therapeutics Receives $1.9 M..
30 September 2026
-
Tolerance Bio Licenses TLB-33 From..
30 September 2026
-
Ascletis Reports Positive Phase I R..
29 September 2026
